5.19

9.49% +0.45

Absci Corp (ABSI)

Overview News Price History Option Chain Discussions Forecast

Absci Corp stock is currently priced at $5.19, with a 24-hour trading volume of 1.04M. It has seen a +9.49% increased in the last 24 hours and a -7.49% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.74 pivot point. If it approaches the $4.98 resistance level, significant changes may occur.

Previous Close:

$4.74

Open:

$4.86

24h Volume:

1.04M

Market Cap:

$586.90M

Revenue:

$5.72M

Net Income/Loss:

$-110.57M

P/E Ratio:

-4.2541

EPS:

-1.22

Net Cash Flow:

$-65.50M

1W Performance:

+14.57%

1M Performance:

-7.49%

6M Performance:

+321.95%

1Y Performance:

+315.20%

1D Range:

$4.805

$5.37

52W Range:

$1.1111

$6.72

Absci Corp Stock (ABSI) Company Profile

Name

Absci Corp

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

360-949-1041

Address

18105 SE Mill Plain Boulevard, Vancouver

Employee

102

Twitter

Next Earnings Date

2024-05-14

Latest SEC Filings

ABSI's Discussions on Twitter

Absci Corp Stock (ABSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-04-23	Initiated	H.C. Wainwright	Buy
Aug-12-22	Downgrade	JP Morgan	Overweight → Underweight
Jul-18-22	Initiated	Truist	Buy
Mar-02-22	Resumed	Cowen	Market Perform
Feb-01-22	Initiated	Berenberg	Buy
Nov-10-21	Downgrade	BofA Securities	Neutral → Underperform
Oct-15-21	Resumed	Cowen	Market Perform
Aug-16-21	Initiated	BofA Securities	Neutral
Aug-16-21	Initiated	Cowen	Market Perform
Aug-16-21	Initiated	Credit Suisse	Outperform
Aug-16-21	Initiated	Stifel	Hold

View All

Absci Corp Stock (ABSI) Latest News

Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?

Zacks Investment Research

BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday

Benzinga

6 Analysts Assess Absci: What You Need To Know

Benzinga

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire Inc.

The Analyst Landscape: 4 Takes On Absci

Benzinga

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire Inc.

Absci Corp Stock (ABSI) Financials Data

Absci Corp (ABSI) Revenue 2024

ABSI reported a revenue (TTM) of $5.72 million for the quarter ending December 31, 2023, a -0.50% decline year-over-year.

Absci Corp (ABSI) Net Income 2024

ABSI net income (TTM) was -$110.57 million for the quarter ending December 31, 2023, a -5.40% decrease year-over-year.

Absci Corp (ABSI) Cash Flow 2024

ABSI recorded a free cash flow (TTM) of -$65.50 million for the quarter ending December 31, 2023, a +32.83% increase year-over-year.

Absci Corp (ABSI) Earnings per Share 2024

ABSI earnings per share (TTM) was -$1.20 for the quarter ending December 31, 2023, a -3.45% decline year-over-year.

Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.